-
3201
-
3202
-
3203
The Relationship between Serum Bilirubin and Inflammatory Bowel Disease
Published 2019-01-01Get full text
Article -
3204
Upper Gastrointestinal Crohn’s Disease: Literature Review and Case Presentation
Published 2019-01-01Get full text
Article -
3205
-
3206
-
3207
-
3208
A Survey on Multisensor Fusion and Consensus Filtering for Sensor Networks
Published 2015-01-01Get full text
Article -
3209
Optimized Control for MMCs with Reduced Power Loss and Extended Lifetime
Published 2024-01-01Get full text
Article -
3210
-
3211
Five-Year Prospective Follow-Up of Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antiviral Agents
Published 2025-01-01“…Yaping Zhang,1,2,* Huan Xia,3,* Luchang Fan,1 Lu Jiang,4 Bin Yang,2 Fengmei Wang4,5 1The Third Central Clinical College of Tianjin Medical University, Tianjin Medical University, Tianjin, 300170, People’s Republic of China; 2Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Institute of Hepatobiliary Disease, Nankai University Affiliated Third Central Hospital, Tianjin, 300072, People’s Republic of China; 3Department of Infectious Diseases, Tianjin Second People’s Hospital, Tianjin, 300192, People’s Republic of China; 4Department of Hepatology and Gastroenterology, Tianjin First Central Hospital, Tianjin, 300192, People’s Republic of China; 5Tianjin Key Laboratory of Molecular Diagnosis and Treatment of Liver Cancer, Tianjin First Central Hospitial, Tianjin, 300192, People’s Republic of China*These authors contributed equally to this workCorrespondence: Fengmei Wang; Bin Yang, Email wangfengmeitj@126.com; bioyang@126.comPurpose: The research intended to present prospective data on the long-term prognosis of individuals with hepatitis C virus (HCV) infection who received direct-acting antiviral agent (DAA) treatment.Patients and Methods: Patients who received DAA treatment at Tianjin Third Central Hospital and Tianjin Second People’s Hospital were prospectively enrolled and subsequently underwent a longitudinal follow-up. …”
Get full text
Article -
3212
Utility of 131I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models
Published 2025-01-01“…Yi Liu,1– 4,* Xiao Wang,1– 3,5,* Ni Zhang,1– 4,* Simin He,1– 4 Jianping Zhang,1– 4 Xiaoping Xu,1– 4 Shaoli Song1– 4 1Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, People’s Republic of China; 3Center for Biomedical Imaging, Fudan University, Shanghai, 200032, People’s Republic of China; 4Shanghai Engineering Research Center of Molecular Imaging Probes, Shanghai, 200032, People’s Republic of China; 5State Key Laboratory of Vaccines for Infectious Diseases, Xiang an Biomedicine Laboratory & Center for Molecular Imaging and Translational Medicine, School of Public Health, Shenzhen Research Institute of Xiamen University, Xiamen University, Xiamen, 361102, People’s Republic of China*These authors contributed equally to this workCorrespondence: Shaoli Song; Xiaoping Xu, Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, 200032, People’s Republic of China, Email shaoli-song@163.com; xxp0012@ustc.eduPurpose: None of the antibody-drug conjugates (ADCs) targeting Claudin 18.2 (CLDN18.2) have received approval from regulatory authorities due to their limited clinical benefits. …”
Get full text
Article -
3213
The adolescent Internet Adaptability Scale: Development and psychometric properties
Published 2025-01-01Get full text
Article -
3214
-
3215
Research Progress in Short-Chain Fatty Acid Modulation of the Gut-Bone Axis in Bone Metabolism
Published 2025-01-01Get full text
Article -
3216
-
3217
Study of charged Lepton Flavor Violation in electron muon interactions
Published 2025-01-01Get full text
Article -
3218
-
3219
-
3220